Asia Pacific Cell and Gene Therapy Market Size and Forecast 2021 - 2031, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Service, Scale, Service Providers, Transfection Reagents, End User, and Country

Description

List of Tables

According to our new research study on "Asia Pacific Cell And Gene Therapy Market Forecast to 2031 -Regional Analysis - by Type, Service, Scale, Service Providers, Transfection Reagents, and End User," the market is anticipated to grow from US$ 1.51 billion in 2024 to US$ 8.98 billion by 2031; the market is expected to register a CAGR of 29.1% from 2025 to 2031. The Asia Pacific cell and gene therapy market growth are attributed to the increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing.

Cell therapy provides the needed working cells for repair or immune defense of the body, whereas gene therapy either adds new genetic instructions or changes the existing ones to fix the disorder or to change the cell's nature. As a result of their combination, the targeted treatments, which are in most cases of a personal nature, can be used for such diseases as cancer, genetic disorders, autoimmune diseases, and degenerative conditions.

The Asia Pacific cell and gene therapy market is categorized into the Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, the Philippines, Vietnam, and the Rest of Asia Pacific. The rising prevalence of genetic disorders, cancers, and chronic diseases has created a strong need for advanced treatment modalities, motivating investment in cell and gene therapy (CGT) research and commercialization. Governments across countries such as China, Japan, South Korea, and Singapore are promoting biotechnology innovation through funding, fast-track regulatory pathways, and infrastructure development, accelerating clinical trial approvals and product launches. Cost-effective manufacturing capabilities and a large, diverse patient population make APAC an attractive hub for global pharmaceutical and biotech companies to conduct trials and expand market access. Increasing awareness of personalized medicine and improvements in healthcare infrastructure contribute to early adoption of advanced therapies. As academic institutions, research organizations, and hospitals collaborate more closely, translational research and technology transfer accelerate, boosting innovation.

According to GLOBOCAN 2022 data from the International Agency for Research on Cancer, China reported approximately 4,824,700 new cancer cases and 2,574,200 cancer deaths. The rising prevalence of cancer is underscoring the urgent need for targeted therapies, such as CAR-T cells. According to a report by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in June 2025, 115 clinical trials for CGT products were registered in 2024, representing a 42% increase from 2023. Companies such as Neukio are exploring allogeneic immune cell technologies, such as iPSC-CAR-NK cells, to address current limitations in cell therapy. These technological advancements enhance the efficiency and scalability of CGT manufacturing, driving the demand for specialized CDMO services. OBiO Technology, a leading CDMO in China specializing in cell and gene therapies, operates 15 GMP-certified vector production lines and 20 GMP cell therapy production lines.

India faces a staggering burden of diseases amenable to cell and gene therapies, particularly cancers and rare genetic disorders, driving urgent innovation in this sector. According to GLOBOCAN 2022 projections from the International Agency for Research on Cancer (IARC), the country recorded 1,413,316 new cancer cases in 2022, contributing to over 900,000 deaths in the same year. Rare genetic diseases affect approximately 70 million Indians, exacerbated by high rates of consanguinity and endogamy that elevate recessive mutation prevalence, with over 450 such conditions documented nationally by the Translational Genomics Institute of Genetics and Society (TIGS). Hemophilia impacts nearly 48,000 individuals with type A alone, based on World Federation of Hemophilia estimates.

The US Food and Drug Administration, National Institute of Health, Asian National Cancer Centers Alliance (ANCCA), are among the primary and secondary sources referred to while preparing the Asia Pacific cell and gene therapy market report.

Product Code: TIPRE00041707

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Asia Pacific Cell and Gene Therapy Market Landscape

4.1 Overview
4.2 Value Chain Analysis
- 4.2.1 Cell and Gene Therapy Market - Value Chain Analysis
- 4.2.2 Raw Material Suppliers / Components
- 4.2.3 Manufacturers Process / Technology
- 4.2.4 Distribution Landscape
- 4.2.5 End User
- 4.2.6 Level of Integration
4.3 Supply Chain Analysis
- 4.3.1 List of Service Providers
- 4.3.2 List of Potential Customers
4.4 Porter's Five Force Analysis
- 4.4.1 Bargaining Power of Suppliers:
- 4.4.2 Bargaining Power of Buyers:
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitutes:
- 4.4.5 Competitive Rivalry:
4.5 PEST Analysis
4.6 Impact of Artificial Intelligence (AI)
4.7 Product/Technology Roadmap
4.8 Sustainability and ESG Trends
- 4.8.1 Environmental Trends
- 4.8.2 Social Trends
- 4.8.3 Governance Trends
4.9 Patent Analysis
4.10 Regulatory Framework and Pipeline Analysis
- 4.10.1 Pipeline Analysis
4.11 Import-Export Analysis

5. Competitive Landscape

5.1 Heat Map Analysis by Key Players
5.2 Company Market Share Analysis, 2024
5.3 Company Market Share Analysis by Top 5 Players, 2024

6. Asia Pacific Cell and Gene Therapy Market - Key Market Dynamics

6.1 Asia Pacific Cell and Gene Therapy Market - Key Market Dynamics
6.2 Market Drivers
- 6.2.1 Increasing Prevalence of Chronic and Genetic Diseases
- 6.2.2 Supportive Government Initiatives
- 6.2.3 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
6.3 Market Restraints
- 6.3.1 High Development and Treatment Costs
- 6.3.2 Complex and Lengthy Regulatory Processes
- 6.3.3 Shortage Of Skilled Professionals and Infrastructure
6.4 Market Opportunities
- 6.4.1 Strategic Initiatives by Companies
- 6.4.2 Expansion of Local Manufacturing Capabilities
- 6.4.3 Rising Investments in R&D and Clinical Trials
6.5 Future Trends
- 6.5.1 Surging Adoption of CRISPR and Advanced Gene Editing Technologies
- 6.5.2 Expansion of Non-Viral Vectors and Allogeneic Therapies
- 6.5.3 Integration of AI for Enhanced Efficiency in Development and Manufacturing
6.6 Impact of Drivers and Restraints:

7. Asia Pacific Cell and Gene Therapy Market Analysis

7.1 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
7.2 Asia Pacific Cell and Gene Therapy Market Forecast and Analysis

8. Asia Pacific Cell and Gene Therapy Market Analysis - by Type

8.1 Cell Therapy
- 8.1.1 Overview
- 8.1.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  - 8.1.2.1 Allogeneic
    - 8.1.2.1.1 Overview
    - 8.1.2.1.2 Allogeneic: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  - 8.1.2.2 Autologous
    - 8.1.2.2.1 Overview
    - 8.1.2.2.2 Autologous: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  - 8.1.2.3 Viral Vectors
    - 8.1.2.3.1 Overview
    - 8.1.2.3.2 Viral Vectors: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Gene Therapy
- 8.2.1 Overview
- 8.2.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  - 8.2.2.1 Non-viral Vectors
    - 8.2.2.1.1 Overview
    - 8.2.2.1.2 Non-viral Vectors: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  - 8.2.2.2 Viral Vectors
    - 8.2.2.2.1 Overview
    - 8.2.2.2.2 Viral Vectors: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Market Analysis - by Service

9.1 Process Development
- 9.1.1 Overview
- 9.1.2 Process Development: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
9.2 cGMP Manufacturing
- 9.2.1 Overview
- 9.2.2 cGMP Manufacturing: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Regulatory Services
- 9.3.1 Overview
- 9.3.2 Regulatory Services: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Bioassay Services
- 9.4.1 Overview
- 9.4.2 Bioassay Services: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Market Analysis - by Scale

10.1 Pre-commercial or R and D Manufacturing
- 10.1.1 Overview
- 10.1.2 Pre-commercial or R and D Manufacturing: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Commercial Scale Manufacturing
- 10.2.1 Overview
- 10.2.2 Commercial Scale Manufacturing: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Market Analysis - by Service Providers

11.1 CDMOs
- 11.1.1 Overview
- 11.1.2 CDMOs: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.2 CMOs
- 11.2.1 Overview
- 11.2.2 CMOs: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Asia Pacific Cell and Gene Therapy Market Analysis - by Transfection Reagents

12.1 Polymer-based Transfection Reagents
- 12.1.1 Overview
- 12.1.2 Polymer-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
12.2 Lipid-based Transfection Reagents
- 12.2.1 Overview
- 12.2.2 Lipid-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
12.3 Viral Transduction Enhancers
- 12.3.1 Overview
- 12.3.2 Viral Transduction Enhancers: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
12.4 Other Transfection Reagents
- 12.4.1 Overview
- 12.4.2 Other Transfection Reagents: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

13. Asia Pacific Cell and Gene Therapy Market Analysis - by End User

13.1 Contract Research Organizations
- 13.1.1 Overview
- 13.1.2 Contract Research Organizations: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
13.2 Pharmaceutical and Biopharmaceutical Companies
- 13.2.1 Overview
- 13.2.2 Pharmaceutical and Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
13.3 Academic and Research Institutes
- 13.3.1 Overview
- 13.3.2 Academic and Research Institutes: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

14. Asia Pacific Cell and Gene Therapy Market - Country Analysis

14.1 Asia Pacific
- 14.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Countries
  - 14.1.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Type
    - 14.1.1.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
    - 14.1.1.1.2 Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
  - 14.1.1.2 Asia Pacific Cell and Gene Therapy Market Breakdown by Service
  - 14.1.1.3 Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
  - 14.1.1.4 Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
  - 14.1.1.5 Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
  - 14.1.1.6 Asia Pacific Cell and Gene Therapy Market Breakdown by End User
- 14.1.2 Asia Pacific Cell and Gene Therapy Market Revenue and Forecast and Analysis - by Country
  - 14.1.2.1 China: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.1.1 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.1.1.1 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.1.1.2 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.1.2 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.1.3 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.1.4 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.1.5 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.1.6 China: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.2 India: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.2.1 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.2.1.1 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.2.1.2 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.2.2 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.2.3 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.2.4 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.2.5 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.2.6 India: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.3 South Korea: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.3.1 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.3.1.1 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.3.1.2 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.3.2 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.3.3 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.3.4 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.3.5 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.3.6 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.4.1 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.4.1.1 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.4.1.2 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.4.2 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.4.3 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.4.4 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.4.5 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.4.6 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.5 Singapore: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.5.1 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.5.1.1 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.5.1.2 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.5.2 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.5.3 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.5.4 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.5.5 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.5.6 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.6 Australia: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.6.1 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.6.1.1 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.6.1.2 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.6.2 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.6.3 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.6.4 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.6.5 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.6.6 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.7 Malaysia: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.7.1 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.7.1.1 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.7.1.2 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.7.2 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.7.3 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.7.4 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.7.5 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.7.6 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.8 Thailand: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.8.1 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.8.1.1 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.8.1.2 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.8.2 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.8.3 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.8.4 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.8.5 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.8.6 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.9 Philippines: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.9.1 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.9.1.1 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.9.1.2 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.9.2 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.9.3 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.9.4 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.9.5 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.9.6 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.10 Vietnam: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.10.1 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.10.1.1 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.10.1.2 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.10.2 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.10.3 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.10.4 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.10.5 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.10.6 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
  - 14.1.2.11 Rest of APAC: Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 14.1.2.11.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
      - 14.1.2.11.1.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
      - 14.1.2.11.1.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
    - 14.1.2.11.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
    - 14.1.2.11.3 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
    - 14.1.2.11.4 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
    - 14.1.2.11.5 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
    - 14.1.2.11.6 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by End User

15. Asia Pacific Cell and Gene Therapy Market Industry Landscape

15.1 Overview
15.2 Product Launch, Product Approvals
15.3 Expansions, Collaboration, Merger and Acquisitions, And Other Strategic Developments

16. Company Profiles

16.1 WuXi AppTec Co Ltd
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
16.2 Lonza Group AG
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
16.3 Syngene International Ltd
- 16.3.1 Key Facts
- 16.3.2 Business Description
- 16.3.3 Products and Services
- 16.3.4 Financial Overview
- 16.3.5 SWOT Analysis
- 16.3.6 Key Developments
16.4 Novotech
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
16.5 SK pharmteco Inc
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
16.6 CMIC Group
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
16.7 Samsung Biologics Co Ltd
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Financial Overview
- 16.7.4 SWOT Analysis
- 16.7.5 Key Developments
16.8 AGC Biologics AS
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
16.9 GenScript Biotech Corporation
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
16.10 Porton Pharma Solutions Ltd
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments
16.11 Lotte Biologics Co Ltd
- 16.11.1 Key Facts
- 16.11.2 Business Description
- 16.11.3 Products and Services
- 16.11.4 Financial Overview
- 16.11.5 SWOT Analysis
- 16.11.6 Key Developments
16.12 Minaris Advanced Therapies
- 16.12.1 Key Facts
- 16.12.2 Business Description
- 16.12.3 Products and Services
- 16.12.4 Financial Overview
- 16.12.5 SWOT Analysis
- 16.12.6 Key Developments
16.13 Cell Therapies Pty Ltd
- 16.13.1 Key Facts
- 16.13.2 Business Description
- 16.13.3 Products and Services
- 16.13.4 Financial Overview
- 16.13.5 SWOT Analysis
- 16.13.6 Key Developments
16.14 Esco Aster Pte. Ltd.
- 16.14.1 Key Facts
- 16.14.2 Business Description
- 16.14.3 Products and Services
- 16.14.4 Financial Overview
- 16.14.5 SWOT Analysis
- 16.14.6 Key Developments
16.15 Aurigene Pharmaceutical Services
- 16.15.1 Key Facts
- 16.15.2 Business Description
- 16.15.3 Products and Services
- 16.15.4 Financial Overview
- 16.15.5 SWOT Analysis
- 16.15.6 Key Developments
16.16 GC Biopharma
- 16.16.1 Key Facts
- 16.16.2 Business Description
- 16.16.3 Products and Services
- 16.16.4 Financial Overview
- 16.16.5 SWOT Analysis
- 16.16.6 Key Developments
16.17 TEIJIN CDMO
- 16.17.1 Key Facts
- 16.17.2 Business Description
- 16.17.3 Products and Services
- 16.17.4 Financial Overview
- 16.17.5 SWOT Analysis
- 16.17.6 Key Developments
16.18 CellVec Pte Ltd
- 16.18.1 Key Facts
- 16.18.2 Business Description
- 16.18.3 Products and Services
- 16.18.4 Financial Overview
- 16.18.5 SWOT Analysis
- 16.18.6 Key Developments
16.19 Avance Clinical Pty Ltd
- 16.19.1 Key Facts
- 16.19.2 Business Description
- 16.19.3 Products and Services
- 16.19.4 Financial Overview
- 16.19.5 SWOT Analysis
- 16.19.6 Key Developments
16.20 Hilleman Laboratories
- 16.20.1 Key Facts
- 16.20.2 Business Description
- 16.20.3 Products and Services
- 16.20.4 Financial Overview
- 16.20.5 SWOT Analysis
- 16.20.6 Key Developments

17. Appendix

17.1 About The Insight Partners
17.2 Glossary of Terms